Symposia - Pre-meetings - Post-meeting


28 June, 08:30-09:30

ViiV Healthcare

Plenary room (N201)

The time 2 optimize HIV treatment with less

This Symposium will focus on the evolution of HIV treatment and discuss 2 Drug Regimens (2DR) as a further shift in the treatment paradigm. Following a review of the history of 2DR evidence and context, the latest updates in 2DR evidence specific to DTG + 3TC, relevant to the Asia / Pac region will be presented and discussed. Real world DTG + 3TC case examples will be shared and discussed and there will be an opportunity for interactive voting and Q&A.

Professor Mark Nelson; Dr Michael Aboud; Dr Soe Than

28 June, 17:00-18:00

Gilead Sciences

Plenary room (N201)

HIV made easy

This symposium will dissect current obstacles in managing HIV in Asia, advances in HIV management over the past decade, and how the new technologies and concepts help streamline the HIV management.

Through live debate and discussion with the audience, Prof. Hung Chien-Ching, Prof. Jürgen Rockstroh and Dr. Damian McColl will deep dive into the latest development of HIV Medicine and what it means to Asia in your clinical practice.

With the integrated experience from Asia and Europe, we can support more people living with HIV and accomplish a full 90-90-90-90* cycle.

* UNAIDS 90-90-90 target and ‘the fourth 90’ – Good health-related quality-of-life.

Prof. Hung Chien-Ching, Prof. Jürgen Rockstroh and Dr. Damian McColl

29 June, 08:30-09:30

ASHM -  Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine


Plenary room (N201)

Navigating the implications of U = U (and V≠V) in clinical practice; a guide for health workers and others

With the release over recent years of findings from now 4 key studies looking at how effectively ART prevents sexual transmission of HIV, it is now clear that for people who take ART daily as prescribed and achieve and maintain an undetectable viral load there is effectively no risk of sexually transmitting the virus to an HIV-negative partner.

This is a major advance, not only for what it means about the central role played by people with HIV in ending new HIV infections, but also because of the major, consequent psychological significance for people with HIV. An understanding of these recent findings can help reduce fear and prejudice that largely underpin HIV-related stigma.

The main purpose of the Undetectable = Un-transmittable campaign is to disseminate accurate and unambiguous information to people with HIV and those at risk, and also challenge HIV-related organisations in government, civil-society and the private sector, to promote awareness and understanding of U=U – this includes health care providers.

Participants understand & explore:

  • The science of U = U
  • Undetectability – what this is and how it is measured
  • The origins of the U = U campaign
  • The language and terminology used in U = U (UVL, VL testing, viral blips, virological failure)
  • Implications for patients for U = U in clinical practice (reduction of anxiety, healthy relationships and confident sex lives which often suffer on diagnosis, incentive to start and adhere to ART, locating condoms more accurately in terms of prevention)
  • Implications for prevention messaging
  • The implications for those who are unable to achieve U = U (i.e.  V≠V)
  • Community and consumer U=U messages & perspectives (non VL options, PrEP and anxiety, PEP and UVL, disclosure – pros and cons and legal context, combination prevention, STIs and regular screening)
  • Obligations for the clinician and best practice guidance available to them
  • Further reading and support for U=U

Scott McGill & Patient Advocate/PLHIV


26-27 June



Room N206-208

The 3rd Asia Pacific HIV Clinical Forum: Integrase Inhibitors

This state-of-the-art program provides challenging plenary lectures (in English) followed by ample time for Q&A and debate, stimulating interaction in order to bridge the knowledge gap between experts and the HIV treating community in Asia Pacific region. The program includes clinical case presentations to discuss real life challenges. And there will be plenty of opportunity to interact with key experts in the field during the meeting as well as during the networking dinner!

Read more>>

27 June, 10:45-12:00

Youth Against AIDS

Room N206-208

Innovation in Prevention - New ways to be relevant in young peoples life

Within the session, for the first time, YAA will present their global best practice projects and give first insights on their digital solution to reach and educate young people worldwide. In the following expert panel discussion the critical role of new tools and ideas on prevention and best practice methods to reach the young generation will be reviewed by the following panelists:

  • Andrew Hexter (Vice President and General Manager Gilead Science, ASIA 5) 
  • Dr. Alex Chiu (Medical Director at AXA Hong Kong)
  • Kitty Choi (Director of Sticky Rice Love)
  • Daniel Nagel (CEO & Chairman of Youth against AIDS)

In a world impacted by major technological and social disruptions "Youth against AIDS“ (YAA) goes new ways to face the HIV & STI epidemic among young generations. YAA is convinced that great innovations are necessary to meet the needs of the young target group, and to become a close partner in young peoples life. YAA builds networks to create innovation in prevention and to create a major change in young peoples individual health management. The claim of our work is: Do what you want. Do it with love, respect and condoms.


29 June, 14:00-17:30


Room N206-208

Symposium on Reducing HIV Stigma and Discrimination for Empowerment

Eliminating stigma and discrimination associated with HIV is one of the main goals of the Fast-Track Cities Initiative, as it presents a barrier to good health care and accessing services. This half-a-day session will address the issues around stigma and discrimination and to develop solutions to solve these issues!